ReviewCurrent opinion in virology2016
Interspecies transmission and chikungunya virus emergence.
Review in Current opinion in virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.
- Visualized analysis of core themes and emerging frontiers in global chikungunya virus studies.Frontiers in microbiology · 2025Pooled it
- Identification and characterization of novel chikungunya virus polymerase inhibitors.Journal of virology · 2026Article
- Chikungunya Virus in 2025: Epidemiology, Immunopathogenesis, and Vaccine Development - A Narrative Review.Infection and drug resistance · 2026Review
- E2 Protein of Chikungunya Virus: A Narrative Review of Its Potential as a Therapeutic Target.Current drug targets · 2026Review
- Genomic characterization and evolutionary analysis of Chikungunya virus strains in Guangzhou, China, 2025.Virology journal · 2025Article
- Rhesus macaques model human Mayaro virus disease and transmit to Aedes aegypti mosquitoes.PLoS neglected tropical diseases · 2025Article
- Challenging the notion of Aedes aegypti as the primary chikungunya virus vector: insights from Kédougou, Southeastern Senegal.BMC infectious diseases · 2025Article
- Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.Nature medicine · 2025Article
- The ecdysone-induced bZIP transcription factor MafB establishes a positive feedback loop to enhance vitellogenesis and reproduction in theProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Global Transmission and Evolution of Chikungunya Virus: Origins, Adaptive Mutations, and Intercontinental Spread of the Three Genotypes.Transboundary and emerging diseases · 2025Article
- Spillover: Mechanisms, Genetic Barriers, and the Role of Reservoirs in Emerging Pathogens.Microorganisms · 2024Review
- Understanding the Transmission Dynamics of the Chikungunya Virus in Africa.Pathogens (Basel, Switzerland) · 2024Review
- The evolutionary and molecular history of a chikungunya virus outbreak lineage.PLoS neglected tropical diseases · 2024Article
- Comparative pathogenesis of three Mayaro virus genotypes in the cynomolgus macaque.The Journal of general virology · 2024Article
- Article
- Ecdysone-controlled nuclear receptor ERR regulates metabolic homeostasis in the disease vector mosquito Aedes aegypti.PLoS genetics · 2024Article
- Translational Control of Alphavirus-Host Interactions: Implications in Viral Evolution, Tropism and Antiviral Response.Viruses · 2024Review
- Spatial-temporal distribution of chikungunya virus in Brazil: a review on the circulating viral genotypes andFrontiers in public health · 2024Review
- Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions.Frontiers in microbiology · 2024Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Chikungunya virus (CHIKV) causes severe, debilitating, often chronic arthralgia with high attack rates, resulting in severe morbidity and economic costs to affected communities. Since its first well-documented emergence in Asia in the 1950s, CHIKV has infected millions and, since 2007, has spread widely, probably via viremic travelers, to initiate urban transmission in Europe, the South Pacific, and the Americas. Some spread has been facilitated by adaptive envelope glycoprotein substitutions that enhance transmission by the new vector, Aedes albopictus. Although epistatic constraints may prevent the impact of these mutations in Asian strains now circulating in the Americas, as well as in African CHIKV strains imported into Brazil last year, these constraints could eventually be overcome over time to increase the transmission by A. albopictus in rural and temperate regions. Another major determinant of CHIKV endemic stability in the Americas will be its ability to spill back into an enzootic cycle involving sylvatic vectors and nonhuman primates, an opportunity exploited by yellow fever virus but apparently not by dengue viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.